Pura Vida Investments Has Lifted Its Globus Med (GMED) Holding; PROTEON THERAPEUTICS (PRTO)’s Sentiment Is 1.57

April 21, 2018 - By Ellis Scott

Globus Medical, Inc. (NYSE:GMED) Logo

PROTEON THERAPEUTICS INC (PRTO) investors sentiment increased to 1.57 in 2017 Q4. It’s up 0.43, from 1.14 in 2017Q3. The ratio improved, as 11 institutional investors increased or started new stock positions, while 7 sold and decreased holdings in PROTEON THERAPEUTICS INC. The institutional investors in our database now own: 7.22 million shares, up from 7.15 million shares in 2017Q3. Also, the number of institutional investors holding PROTEON THERAPEUTICS INC in top ten stock positions was flat from 3 to 3 for the same number . Sold All: 2 Reduced: 5 Increased: 5 New Position: 6.

Pura Vida Investments Llc increased Globus Med Inc (GMED) stake by 82.5% reported in 2017Q4 SEC filing. Pura Vida Investments Llc acquired 82,500 shares as Globus Med Inc (GMED)’s stock rose 22.30%. The Pura Vida Investments Llc holds 182,500 shares with $7.50 billion value, up from 100,000 last quarter. Globus Med Inc now has $5.04B valuation. The stock increased 1.98% or $1.01 during the last trading session, reaching $52.09. About 833,742 shares traded or 36.45% up from the average. Globus Medical, Inc. (NYSE:GMED) has risen 65.36% since April 21, 2017 and is uptrending. It has outperformed by 53.81% the S&P500.

Among 15 analysts covering Globus Medical Inc (NYSE:GMED), 9 have Buy rating, 2 Sell and 4 Hold. Therefore 60% are positive. Globus Medical Inc had 49 analyst reports since August 3, 2015 according to SRatingsIntel. The stock of Globus Medical, Inc. (NYSE:GMED) earned “Neutral” rating by Bank of America on Friday, November 10. The company was maintained on Wednesday, July 27 by Barclays Capital. Piper Jaffray maintained the shares of GMED in report on Tuesday, January 9 with “Buy” rating. UBS initiated Globus Medical, Inc. (NYSE:GMED) on Tuesday, September 22 with “Buy” rating. The company was maintained on Thursday, August 17 by Piper Jaffray. The stock has “Perform” rating by Oppenheimer on Wednesday, November 9. The company was initiated on Friday, May 27 by Barclays Capital. Canaccord Genuity maintained it with “Buy” rating and $53.0 target in Thursday, February 22 report. On Wednesday, March 28 the stock rating was maintained by Leerink Swann with “Buy”. The stock has “Underweight” rating by Barclays Capital on Thursday, November 9.

Pura Vida Investments Llc decreased Envision Healthcare Corp stake by 33,192 shares to 90,000 valued at $3.11 billion in 2017Q4. It also reduced Penumbra Inc stake by 44,579 shares and now owns 15,000 shares. Dentsply Sirona Inc was reduced too.

Investors sentiment decreased to 0.99 in Q4 2017. Its down 0.39, from 1.38 in 2017Q3. It worsened, as 26 investors sold GMED shares while 83 reduced holdings. 40 funds opened positions while 68 raised stakes. 59.89 million shares or 7.54% less from 64.77 million shares in 2017Q3 were reported. Us Bancorporation De has 0% invested in Globus Medical, Inc. (NYSE:GMED). 5.94 million were accumulated by Vanguard Grp Incorporated. Lpl Ltd stated it has 0% in Globus Medical, Inc. (NYSE:GMED). Huntington Bancorp invested 0% in Globus Medical, Inc. (NYSE:GMED). Nordea invested in 73,514 shares. Qs Invsts stated it has 1,615 shares. Goldman Sachs Group accumulated 0% or 381,218 shares. Martingale Asset Limited Partnership has 0.01% invested in Globus Medical, Inc. (NYSE:GMED). Shelton Capital Mgmt reported 5,432 shares. Tradewinds Cap Mngmt Limited Company invested in 0.01% or 345 shares. California State Teachers Retirement Sys holds 111,225 shares or 0.01% of its portfolio. Gam Hldg Ag stated it has 37,371 shares or 0.05% of all its holdings. Moreover, Northwestern Mutual Wealth Management has 0% invested in Globus Medical, Inc. (NYSE:GMED). Teachers Retirement System Of The State Of Kentucky holds 53,147 shares or 0.03% of its portfolio. Cap Impact Advisors Ltd Liability Corp owns 46,636 shares for 0.83% of their portfolio.

Analysts await Proteon Therapeutics, Inc. (NASDAQ:PRTO) to report earnings on May, 9. They expect $-0.35 EPS, up 10.26% or $0.04 from last year’s $-0.39 per share. After $-0.31 actual EPS reported by Proteon Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 12.90% negative EPS growth.

Since January 1, 0001, it had 1 insider purchase, and 0 selling transactions for $22,560 activity.

The stock decreased 6.12% or $0.15 during the last trading session, reaching $2.3. About 106,940 shares traded or 168.87% up from the average. Proteon Therapeutics, Inc. (PRTO) has risen 59.38% since April 21, 2017 and is uptrending. It has outperformed by 47.83% the S&P500.

Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular diseases. The company has market cap of $40.65 million. It develops vonapanitase, a recombinant human elastase, which is in Phase III clinical trial for patients with chronic kidney disease undergoing surgical creation of a radiocephalic fistula for hemodialysis; has completed a Phase I/II clinical trial in patients undergoing placement of an arteriovenous graft; and is in Phase I clinical trial for the treatment of symptomatic peripheral artery disease. It currently has negative earnings.

Abingworth Llp holds 2.7% of its portfolio in Proteon Therapeutics, Inc. for 2.02 million shares. Deer Vii & Co. Ltd. owns 315,101 shares or 2.42% of their US portfolio. Moreover, Mpm Asset Management Llc has 0.75% invested in the company for 983,381 shares. The Massachusetts-based Ra Capital Management Llc has invested 0.21% in the stock. Perceptive Advisors Llc, a New York-based fund reported 334,116 shares.

Proteon Therapeutics, Inc. (NASDAQ:PRTO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Ellis Scott

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: